Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Down Syndrome 1

Interventions

Methotrexate 48Cyclophosphamide 47Vincristine 39Cytarabine 36Dexamethasone 33Mercaptopurine 32pegaspargase 30Doxorubicin 29Daunorubicin 26Etoposide 24Asparaginase 23Prednisone 22Radiotherapy 18Thioguanine 15Leucovorin 14Calcium Dobesilate 14merphos 12Prednisolone 12blinatumomab 11Hydrocortisone 10Whole-Body Irradiation 9dexamethasone acetate 8azathiopurine 8Methylprednisolone 8Ifosfamide 8Filgrastim 8Cyclosporine 8fludarabine 7dexamethasone 21-phosphate 7auricularum 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × N,N-dicyclohexyl-isoborneol-10-sulfonamide × Clear all
NCT02003222 2026-05-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
488 enrolled 13 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡